Description
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Indications:
-
Postprandial hyperglycemia in patients with Type 2 Diabetes Mellitus
-
Used as monotherapy or in combination with other oral antidiabetic agents
Pharmacology:
Voglibose is an alpha-glucosidase inhibitor. It delays the digestion and absorption of carbohydrates in the intestine, thereby reducing the rise in blood glucose after meals.
Dosage & Administration:
-
Usual dose: 0.2 mg orally, 3 times daily before meals
-
Dosage may be adjusted based on blood glucose monitoring
-
Should be taken immediately before each main meal
Interaction:
-
May enhance hypoglycemic effect when used with sulfonylureas or insulin
-
Concurrent use with other alpha-glucosidase inhibitors should be avoided
-
Antacids and digestive enzymes may affect efficacy
Contraindications:
-
Hypersensitivity to Voglibose or any component of the formulation
-
Patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or predisposition to intestinal obstruction
-
Severe renal or hepatic impairment
Side Effects:
-
Common: Flatulence, abdominal bloating, diarrhea
-
Less common: Nausea, abdominal pain
-
Rare: Liver enzyme elevation, allergic reactions
Pregnancy & Lactation:
-
Pregnancy: Use only if clearly needed and under medical supervision
-
Lactation: Use with caution; insufficient data on safety during breastfeeding
Precautions & Warnings:
-
Monitor liver function regularly
-
Not effective for patients with Type 1 diabetes
-
Should not be used during episodes of ketoacidosis or severe infection
Therapeutic Class:
Alpha-glucosidase inhibitors – Oral Antidiabetic Agent
Storage Conditions:
Store below 30°C in a dry, cool place, away from direct sunlight. Keep out of reach of children.
.jpg)
Change Language